Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 10;8:599389. doi: 10.3389/fcell.2020.599389

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Wang, Gao, Zheng, Chen, Ma, Shen, Qu, Zhang, Gurney, O’Donnell and Xu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Immunoblot analysis for the ratio of p-Akt to Akt in the hippocampus. The ratio of p-Akt to Akt is decreased after scopolamine treatment, but reversed by 0.01 and 0.03 mg/kg BPN14770 (A). Pre-treatment with H89 (B), Sirtinol (C), or MK-2206 (D) prevented the therapeutic effects of BPN14770. Results are displayed as mean ± S.E.M. (n = 4–5 per group). ^∗∗∗P < 0.001 vs. vehicle-treated control group; ^#P < 0.05, ^##P < 0.01, and ^###P < 0.001 vs. vehicle-treated scopolamine group; ^$P < 0.05 and ^$$P < 0.01 vs. BPN-treated scopolamine group. Rol, rolipram; Sirt, Sirtinol; and MK, MK-2206.